State drug price transparency laws continue to proliferate across the country and bring with them additional work for government price reporting teams and risk of penalties for manufacturers. Key topics include:

• Identifying states with current and pending drug price transparency laws
• Manufacturer notification and justification requirements
• Enforcement actions taken under existing laws
• Addressing challenges with finding solutions for reporting under non-uniform and sometimes conflicting state laws
• Providing tips for developing a system to track and respond to these laws
• Discussing the impact of these laws on Medicaid and other state pricing
• Evaluating recent litigation, enforcement actions, and judicial developments shaping state transparency requirements